Effects of intravitreal bevacizumab therapy on glomerular filtration rates in patients treated for proliferative diabetic retinopathy

Conclusion: Increased number of intravitreal bevacizumab injections at therapeutic dosage was not associated with reduced GFR in patients with proliferative diabetic retinopathy. This study supports that intravitreal antivascular endothelial growth factor agents are renally safe.
Source: RETINA - Category: Opthalmology Tags: Original Study Source Type: research